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Abstract The objective of this study is to evaluate the
effectiveness and safety of total disc replacement surgery
compared with spinal fusion in patients with symptomatic
lumbar disc degeneration. Low back pain (LBP), a major
health problem in Western countries, can be caused by a
variety of pathologies, one of which is degenerative disc
disease (DDD). When conservative treatment fails, surgery
might be considered. For a long time, lumbar fusion has
been the ‘‘gold standard’’ of surgical treatment for DDD.
Total disc replacement (TDR) has increased in popularity
as an alternative for lumbar fusion. A comprehensive sys-
tematic literature search was performed up to October
2008. Two reviewers independently checked all retrieved
titles and abstracts, and relevant full text articles for
inclusion. Two reviewers independently assessed the risk
of bias of included studies and extracted relevant data and
outcomes. Three randomized controlled trials and 16 pro-
spective cohort studies were identiﬁed. In all three trials,
the total disc replacement was compared with lumbar
fusion techniques. The Charite ´ trial (designed as a non-
inferiority trail) was considered to have a low risk of bias
for the 2-year follow up, but a high risk of bias for the
5-yearfollowup.TheCharite ´ artiﬁcialdiscwasnon-inferior
to the BAK
 Interbody Fusion System on a composite
outcome of ‘‘clinical success’’ (57.1 vs. 46.5%, for the
2-year follow up; 57.8 vs. 51.2% for the 5-year follow up).
There were no statistically signiﬁcant differences in mean
pain and physical function scores. The Prodisc artiﬁcial
disc (also designed as a non-inferiority trail) was found to
be statistically signiﬁcant more effective when compared
with the lumbar circumferential fusion on the composite
outcome of ‘‘clinical success’’ (53.4 vs. 40.8%), but the
risk of bias of this study was high. Moreover, there were no
statistically signiﬁcant differences in mean pain and
physical function scores. The Flexicore trial, with a high
risk of bias, found no clinical relevant differences on pain
and physical function when compared with circumferential
spinal fusion at 2-year follow up. Because these are pre-
liminary results, in addition to the high risk of bias, no
conclusions can be drawn based on this study. In general,
these results suggest that no clinical relevant differences
between the total disc replacement and fusion techniques.
The overall success rates in both treatment groups were
small. Complications related to the surgical approach ran-
ged from 2.1 to 18.7%, prosthesis related complications
from 2.0 to 39.3%, treatment related complications from
1.9 to 62.0% and general complications from 1.0 to 14.0%.
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DOI 10.1007/s00586-010-1445-3Reoperation at the index level was reported in 1.0 to 28.6%
of the patients. In the three trials published, overall com-
plication rates ranged from 7.3 to 29.1% in the TDR group
and from 6.3 to 50.2% in the fusion group. The overall
reoperation rate at index-level ranged from 3.7 to 11.4% in
the TDR group and from 5.4 to 26.1% in the fusion group.
In conclusion, there is low quality evidence that the Charite ´
is non-inferior to the BAK cage at the 2-year follow up on
the primary outcome measures. For the 5-year follow up,
the same conclusion is supported only by very low quality
evidence. For the ProDisc, there is very low quality evi-
dence for contradictory results on the primary outcome
measures when compared with anterior lumbar circumfer-
ential fusion. High quality randomized controlled trials
with relevant control group and long-term follow-up is
needed to evaluate the effectiveness and safety of TDR.
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Introduction
Low back pain is a major health problem in Western
countries [1, 2]. A variety of pathologies can cause low
back pain, one of which is degenerative disc disease (DDD)
[3]. It has been hypothesised that through disc dehydration,
annular tears, and loss of disc height or collapse, DDD
can result in abnormal motion of the segment and bio-
mechanical instability causing pain [4–7].
When conservative treatment fails, patients and health
care providers may consider other treatment options such
as surgery. Although the rationale for surgery is often not
clear and despite the lack of convincing evidence in the
literature regarding the effectiveness of surgery in the
treatment of symptomatic DDD, the number of surgical
procedures performed is continually increasing [8, 9]. For a
long time, lumbar fusion (arthrodesis) has been the ‘‘gold
standard’’ surgical treatment for DDD. However, long-term
results are poor and complications common [4, 10].
An alternative surgical procedure, total disc replace-
ment, has increased in popularity. The purpose of this
technique is to restore and maintain spinal segment motion,
which is assumed to prevent adjacent level degeneration at
the operated levels, while relieving pain [4, 11–13].
Replacing a degenerated joint instead of fusing it was
considered for the spine due to the success of total knee and
hip arthroplasty [5, 14, 15]. The ﬁrst described total disc
replacement was the Fernstorm steelball endprosthesis in
the late 1950s [16]. Since that time, multiple disc
replacement prostheses have been designed for use in the
lumbar spine. A large majority would never be implanted
in humans [4, 10, 17]. The ﬁrst prosthesis designed to be
commercially distributed as an artiﬁcial disc was initiated
in 1982 by Schellnack and Buttner-Janz. Currently, many
different lumbar total disc prostheses are available and
approved for the European market. In the United States,
American Investigational Device Exemption (IDE) trials
have let to FDA approval for Charite ´ and Prodisc
prostheses.
In this article, we systematically review the available
literature on the effectiveness and safety of currently
available prostheses for TDR in patients with systematic
DDD.
Materials and methods
Objective
The objective of this systematic review was to assess the
effectiveness and safety of total disc replacement surgery
in patients with chronic low back pain due to DDD. The
main research questions were:
1. What is the course of DDD complaints and/or symp-
toms following total disc replacement surgery?
2. What is the effectiveness of total disc replacement
surgery compared to other treatments?
3. What is the safety of total disc replacement surgery?
For this systematic review, we used the method guide-
lines for systematic reviews as recommended by the
Cochrane Back Review Group [18]. Below the search
strategy, selection of the studies, data extraction, risk of
bias assessment, and data analysis are described in more
detail. All these steps were performed by two reviewers
independently (KvdE and RO) and during consensus
meetings, potential disagreements between the two
reviewers regarding these issues were discussed. If they
were not resolved a third reviewer (MvT) was consulted.
Search strategy
An experienced librarian performed a comprehensive sys-
tematic literature search. The MEDLINE, EMBASE and
COCHRANE LIBRARY databases were searched for rele-
vant studies from 1973 to October 2008. The search
strategy consisted of a combination of keywords concern-
ing the technical procedure (e.g. disc replacement, pros-
thesis, implantation, discectomy, arthroplasty) and
keywords regarding the anatomical features and pathology
(e.g. intervertebral disc degeneration, discitis, low back
pain, lumbosacral region, lumbar vertebrae). These key-
words were used as MESH headings and free text words. In
addition, a search was performed using the speciﬁc names
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request.
Selection of studies
The search was limited to studies published in English,
German, and Dutch, because these are the languages that
the review authors are able to read and to understand. Two
review authors independently examined all titles and
abstracts that met our search terms and reviewed full
publications, when necessary. The reference section of all
primary studies was inspected for additional references.
For the assessment of the course of complaints and/or
symptoms (research question 1), we included prospective
cohort studies reporting on at least 20 cases and having a
follow up period of more than 6 weeks. By deﬁnition,
cohort studies do not provide information about effective-
ness, so for assessment of the effectiveness (research
question 2), we only included randomized controlled trials.
When multiple articles were identiﬁed on the same study,
but describing different follow up measurements, they were
included. However, articles describing only one arm of the
trial, or only describing the results of 1 centre of a multi-
centre trial were excluded. For assessing the safety
(research question 3), we extracted data on all reported
complications from the prospective cohort studies and
randomized controlled trials we included for research
questions 1 and 2. Furthermore, we included overview
studies on complications. Case reports were excluded.
Data extraction
Two review authors independently extracted relevant data
from the included studies regarding design, population (e.g.
age, gender, duration of complaints), type of total disc
replacement surgery, type of control intervention (e.g. no
treatment, lumbar fusion), vertebral level(s) operated on,
follow-up period, and outcomes. Primary outcomes that
were considered relevant were pain intensity [e.g. visual
analogue scale (VAS), functional status, e.g. Roland Morris
Disability Scale, Oswestry Scale (ODI), global improve-
ment and return to work]. All ODI scores and VAS scores
were converted into 0–100 scale. Other outcome measures,
such as physiological outcome, radiological outcomes, and
patient satisfaction were considered as secondary outcome
measures.
Risk of bias (RoB) assessment
Two review authors independently assessed the risk of bias
(RoB) of the included studies. Controlled trials were
assessed using a criteria list recommended by the Cochrane
Back Review Group [18]. The following criteria are scored
yes, no or unsure: (1) Was the method of randomization
adequate? (2) Was the treatment allocation concealed? (3)
Was the patient blinded to the intervention? (4) Was the
care provider blinded to the intervention? (5) Was the
outcome assessor blinded to the intervention? (6) Was
the dropout rate described and acceptable? (7) Were all
randomized participants analyses in the group to which
they were allocated? (8) Are reports of the study free of
suggestion of selective outcome reporting? (9) Were the
groups similar at baseline regarding the most important
prognostic indicators? (10) Were co-interventions avoided
or similar? (11) Was compliance acceptable in all groups?
(12) Was the timing of the outcome assessment similar in
all groups? Criteria 11 was scored not applicable because
we consider compliance not relevant for surgical inter-
ventions. If studies met at least 6 of the 12 items, the RoB
was considered low. Disagreements were resolved in a
consensus meeting and a third review author was consulted
when necessary. Full assessment is available upon request.
The overall grading of the evidence was based on the
GRADE approach [19].
Results
Search and selection
A total of 1,962 references were identiﬁed from MED-
LINE, EMBASE and the COCHRANE LIBRARY that
were potentially relevant for this review on total disc
replacement surgery. After checking titles and abstracts, a
total of 112 full text articles were retrieved that were
potentially eligible for answering all research questions.
After reading full text, 21 articles reporting on 16 studies
were relevant for answering research question 1, and 16
articles reporting on 3 studies were relevant for research
question 2. Seven overview articles for answering research
question 3. Figure 1 shows the search strategy process in a
ﬂow diagram. Reviewing the reference lists of these arti-
cles resulted in no additional studies.
Type of studies
For assessing the course of DDD complaints and/or
symptoms (research question 1) 16 prospective cohort
studies were included, describing four different devices, 6
for Charite ´ [20–26], 8 for Prodisc [27–36], 1 for Maverick
[37–39], and 1 for Acroﬂex [40]. For assessing the effec-
tiveness of total disc replacement (research question 2), we
identiﬁed three randomized controlled trials, all conducted
in the USA in order to get FDA approval. Each trial
examined a different prostheses for TDR (Charite ´, and
ProDisc and Flexicore) and all used fusion (although
1264 Eur Spine J (2010) 19:1262–1280
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paring TDR surgery to other treatments were found. Two
trials (Charite ´ and ProDisc trial) were described in multiple
articles [6, 10, 13, 41–53]. Given our inclusion and
exclusion criteria, we ﬁnally included two articles
describing the Charite ´ trial; one reporting the 24 months
follow up [10] and the other the 5-year follow up [51].
However, 5-year follow-up results were only available of
57% of the originally randomized population. We included
one article for the ProDisc trial reporting the 24-month
follow-up results [52]. The Flexicore trial was described in
one article, which should be considered as preliminary
results as the ﬁnal results of this trial have not yet been
published [53] (Table 1).
Assessment of risk of bias
After assessing, the risk of bias of the controlled trials there
was 20% disagreement between the two review authors.
Consultation of the third reviewer was not necessary
because disagreements were resolved in a consensus
meeting. For the 24 months follow up, the reporting on the
Charite ´ trial was considered to have a low risk of bias.
However, the reporting on the 5-year follow up was con-
sidered to have a high risk of bias. The reporting on the
ProDisc trial was considered to have a high risk of bias as it
only met 4 out of the 11 risk of bias criteria. The Flexicore
study was also considered to have a high risk of bias as it
only met 2 out of 11 risk of bias criteria (Table 2). By
design, the prospective cohort studies were not only
included in the effectiveness analysis, but also used to
describe the course of DDD complaints and/or symptoms
after undergoing a TDR surgery.
Outcomes
(1) What is the course of DDD complaints and/or
symptoms following total disc replacement surgery?
Charite ´
 (Table 3) The Charite ´ prostheses is the ﬁrst
total disc prostheses, developed by Butter-Janz and
Schellnack at the Charite ´ clinic in former East Germany.
The Charite ´III became commercially available for the ﬁrst
time in the late 1980s [54, 55]. Lemaire et al. reported 2
articles, respectively, with 51 months follow-up in 1997
[20] and with 11.3 years follow up in 2005 [23] on the
same population. These articles report a good or excellent
clinical result, respectively, in 85 and 90%. Several other
prospective cohort studies report positive results as well on
VAS improvement (range 16–66 points), ODI improve-
ment (range 14–51%) and patients’ satisfaction (range 69–
92%) [21–26].
ProDisc
 (Table 3) The ProDiscI was developed in
France by Marnay, who operated on 64 patients and per-
formed a single or multi-level total disc replacement in the
beginning of the 1990s [29, 54, 55]. Fifty-ﬁve patients were
available for follow-up after average 8.7 years. 82.6% of
Title and abstract review
Full text review
MEDLINE 1513 articles 
EMBASE 1102 articles after checking for duplicates:  
1962 articles 
COCHRANE             171 articles 
116 articles 
Prospective controlled  
3 studies reported in 
16 articles 
Prospective cohort 
16 studies reported in 
21 articles 
Charité
1 study reported in 
8 articles 
ProDisc
1 study reported in 
7 articles 
Flexicore 
1 study reported in 
1 article 
Charité
6 studies reported in 
7 articles 
ProDisc 
8 studies reported in 
10 articles 
Maverick 
1 study reported in 
3 articles 
Acroflex 
1 study reported in 
1 article, 
Cost-efficiency 
3 articles 
Complications 
Included: 
7 overview articles 
2 FDA reports 
plus included studies: 
- 16 prospective cohort studies 
- 3 prospective controlled trials 
Fig. 1 Flow diagram
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123the patients were ‘‘completely satisﬁed’’ or ‘‘satisﬁed’’ with
the results [29]. ProDiscII, the second generation ProDisc,
is reported on in several publications with follow up range
3 months to 2 years [27, 28, 30–36]. Primary outcome
results suggest being positive, VAS improvement (range
40–62 points) and ODI improvement (range 21–48%).
Moreover, the majority of patients seem to be satisﬁed with
the results (range 79–100%).
Maverick
 (Table 3) Huec et al. published several stud-
ies on the Maverick device [37–39]. At 2-year follow-up
improvement was reported in VAS for low back pain and
leg pain, decreasing by 44 and 18 points, respectively.
Functional status improved as ODI score decreased 20.7%,
and an overall improvement in functional status of 25%
occurred in 75% of the patients. Since 2003, a prospective
controlled trial has been ongoing in the USA [54].
Acroﬂex
 (Table 3) Fraser et al. [40] conducted two pilot
studies and combined the results. The endplates were
changed for the second study because of device failure. For
the whole group, the functional impairment (ODI)
improved from 14.9% and the Low Back Pain Score
(LBPS) improved from 17.7 to 33 at 24 months follow-up.
50% of the patients were not working because of their back
condition. Due to detection of mechanical failure, the
randomized controlled trial has not been carried out.
In conclusion, many studies suggest pain relief,
improvement in functional status and patient satisfaction
after TDR surgery. The overall outcome is positive,
reduction of pain intensity (range 16–66 points) and
improvement of functional impairment (range 14–51%).
Moreover, the majority of patients seem to be satisﬁed with
the results (range 69–100%). Unfortunately, detailed
information on how outcomes were measured was often
lacking. Although outcome results from observational
studies suggest a positive course after TDR surgery, a
drawback is that a signiﬁcant amount of complications was
reported as well (which will be described later), and a
control group was lacking in these studies.
(2) What is the effectiveness of total disc replacement
surgery compared to other treatments?
Charite ´
 trial (Table 1) The Charite ´ trial [10, 51], which
was designed as a non-inferiority trail, randomized 304
patients to either TDR with the Charite ´ III disc (n = 205)
or anterior interbody fusion with BAK cage (n = 99) with
a follow-up of 2 and 5 years. The primary outcomes were
pain (VAS), functional impairment (ODI), overall clinical
success (deﬁned by using four criteria: C25% improve-
ment in ODI, device failure, major complications, and
neurological deterioration). As a secondary outcome,
patient satisfaction was measured. The improvements on
pain intensity (-40.6 vs. -34.1) and functional impairment
(24.3 vs. 21.6%), for the TDR and the BAK, respectively,
did not differ signiﬁcantly at 2-year follow up. The overall
clinical success (indeed statistically tested on non-inferi-
ority) revealed that the Charite ´ group was non-inferior to
the lumbar fusion group (57.1 vs. 46.5%; P\0.0001.
P value based on the Blackwelder’s test for equivalence).
Patient satisfaction was signiﬁcantly better in the Charite ´
group (73.7%) compared to the control group (53.1%)
(P\0.002). 5-year results, based on only 57% of the
randomized patients and with a high risk of bias, were
broadly in line with the 2-year results. At 5-year follow-up,
outcomes on the composite score of clinical success
showed that the Charite ´ was non-inferior to the lumbar
fusion group (57.8 vs. 51.2%; P\0.04. P value based on
the Blackwelder’s test for equivalence) [51]. There were no
statistically signiﬁcant differences in functional impair-
ment and pain intensity. In conclusion, there is low quality
evidence (based on one study only with a low risk of bias)
that there are no clinically relevant differences on the
Table 2 Methodological quality prospective controlled studies
Trial A1 B2 C3 C4 C5 D6 D7 E8 F9 F10 F11
a F12 Risk of bias
FlexiCore
 Sasso et al. [53] U U N N N N N U Y U NA Y 2/11 (high)
ProDisc
 Zigler et al. [52] Y U N N N N N Y Y U NA Y 4/11 (high)
Charite ´
 Blumenthal et al. [10]
Guyer et al. [51]
Y Y N N N Y Y Y Y U NA Y 7/11 (low)
b
Y Y N N N Y N Y Y U NA Y 6/11 (low)
c
Y Y N N N N U Y Y U NA Y 5/11 (high)
d
U unsure, Y yes, N no, NA not applicable
a Criteria 11 was scored
b For overall measures, 2 year follow-up
c For VAS en ODI outcome, 2 year follow-up
d For 5 year follow-up
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Study/author Indication
in/exclusion criteria
Demografy/
type of disc for TDR/
Level of intervention
Follow up: duration and outcome
Charite ´
Zeegers et al.
[21]
Indication/diagnosis:
discopathy (40)
post-discectomy discopathies (29)
discopathy with possible disc protrusion (6)
Exclusion criteria:
predominant symptoms or deﬁcits in the legs related to
involvement of the nerve roots, spondylolisthesis, spinal
stenosis, altered posterior elements, infection, metabolic
bone diseases (e.g. osteoporosis, osteomalacia), severe
scarring after previous surgery, insufﬁcient motivation of the
patient.
N = 50 $30 #20
mean 43 years (range
24–59 years)
Type: Charite ´ III

Level:
1-level L5/S1 (n = 8),
L4/L5 (n = 16),
L3/L4 (n = 5)
2-level L4/L5/S1
(n = 12)
L3/L4/L5 (n = 5)
L5/S1and L3/L4
(n = 1)
3-level L3/L4/L5/S1
(n = 3)
Follow up: 24 months
8–32% lost to follow up
Low Back pain (improvement): 65% (30/46)
Leg pain (improvement): 64% (27/42)
Return to work: 81% (35/43)
Narcotic use (decrease): 30% (15/34)
Patient Satisfactory (no regret of surgery):
83% (38/46)
Overall clinical results (Stauffer Coventry
Scale): Good and fair: 70% (32/46), Poor:
30% (14/46)
Complication: n = 52 (in 30
patients = 60%)
Re-operation: (n = 7) 14%
Regan [22] Indication/Diagnosis:
DDD, sympthomatic
Inclusion criteria
age between 18–60 years, single level DDD, contained
herniated nucleus pulposus, paucity of facet joint
degeneration, primary complaint of back pain, failed
conservative treatment for at least 6 months, a minimum
disc height of 4 mm, scarring/thickening of the annulus
ﬁbrosis with osteophytes indicating osteoarthritis.
Exclusion criteria:
previous thoracic or lumbar fusion, previous surgery on the
effected level (except prior discectomy, nondestabilizing
laminectomy/otomy without facetectomy, or nucleosis),
osteoporosis or metabolic bone disease, radiculair leg pain,
lumbar scoliosis, stenosis, segmental instability,
spondylosis, spondylolisthesis, spinal neoplasm, active
systemic or local infection, facet joint arthrosis, pregnancy,
history of chronic steroid use, arachnoiditis, metal allergy,
autoimmune disorders, psychosocial disorder, previous
retroperitoneal or[3 intra-abdominal operations
N = 100 $46 #54
mean 43 years (range
24–59 years)
Type: Charite ´ III

Level:
1-level L5/S1 (n = 68)
L4/L5 (n = 32)
Follow up: 6 months (6 weeks, 3, 6 months)
0% lost to follow up
Pain (VAS): pre-op: 73.2 (SD14.5), follow
up: 39.2 (SD26.4), difference: -34.0
Functional status (ODI): pre-op 53.4%
(SD13.4) follow up: 37.6% (SD18.6),
difference: -15.8%
Complication: n = 9 (10%)
Re-operation: n = 7 (7.0%)
Lemaire et al.
[20, 23]
Indication/Diagnosis:
DDD, sympthomatic
Inclusion criteria
failed conservative treatment
Exclusion criteria:
obesity, prior fusion, instability such as spondylolisthesis,
deformity, radicular pain symptomology, presence of facet
arthrosis
N = 100 $59 #41
mean 40 years (range
24–51 years)
Type: Charite ´ III

Level:
1-level: (n = 54)
2-level: (n = 45)
3-level: (n = 1)
L5/S1 (n = 72)
L4/L5 (n = 69)
L3/L4 (n = 6)
Follow up: mean 11.3 months (range 10–
13.4 years)
7% lost to follow up (n = 107 originally
included)
Return to work: 91.6% (87/95)
Overall clinical results (Stauffer Coventry
Scale): Excellent: 62%, Good: 28%, Poor:
10%
Complication: n = 16 (16%)
Re-operation: n = 5 (5%)
Ross et al.
[24]
Indication/Diagnosis:
DDD, sympthomatic
Inclusion criteria
failed conservative treatment, ODI[30%
Exclusion criteria:
spondylolisthesis
N = 160 $98 #62
mean 46 years (range
27–73 years)
Type: Charite ´ III

Level:
L5/S1 (n = 114)
L4/L5 (n = 92)
L3/L4 (n = 20)
Follow up: mean 79 months (range 31–161
months)
23.1% lost to follow up
Pain (VAS): pre-op*: 63, follow up**: 47,
difference: -16
Functional status (ODI): pre-op*: 51% (26–
90) follow up**: 37% (0–90) difference:
-14%
Patient Satisfactory**: ‘‘much better’’ 41%,
‘‘better’’ 28%, ‘‘same as before’’ 11%,
‘‘worse than before’’ 20%
Complication: n = 53 (33.1%)
Re-operation: n = 12 (7.5%)
*(n = 77/160), **(n = 123/160)
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Study/author Indicationin/exclusion criteria Demografy/type of disc
for TDR/Level of
intervention
Follow up: duration and outcome
Gioia et al.
[25]
Indication/Diagnosis:
DDD, sympthomatic
Exclusion criteria:
disc herniation, spinal canal stenosis, spondylolysis,
osteoporosis.
N = 36 $23 #13
mean 40 years (range
32–49 years)
Type: Charite ´ III

Level:
1-level: (n = 28)
2-level: (n = 7)
3-level: (n = 1)
L5/S1 (n = 15)
L4/L5 (n = 11)
L3/L4 (n = 2)
Follow up: mean 6.9 years (range 5–9 years)
lost to follow up not mentioned
Pain (VAS): pre-op: 80 (75–83), follow up:
14 (9–19), difference: -66
Functional status (ODI): pre-op: 44% (39.3–
48.7), follow up: 9% (5.4–12.2),
difference: -35%
Patient Satisfactory: ‘‘excellent’’ 72%,
‘‘good’’ 20%, ‘‘inadequate’’ 4%, ‘‘poor’’
4%
Surgery again?: ‘yes’92% (33/36)
Complication: n = 11 (30.6%)
Re-operation: n = 5 (13.9%)
Warachit [26] Indication/Diagnosis:
DDD, sympthomatic
N = 43 $17 #26
mean 42 years (range
23–54 years)
Type: Charite ´ III

Level:
1-level: (n = 36)
2-level: (n = 7)
L5/S1 (n = 16)
L4/L5 (n = 33)
L3/L4 (n = 1)
Follow up: 3 years
lost to follow up not mentioned
Pain (VAS): pre-op: 74, follow up: 13,
difference: -61
Functional status (ODI): pre-op: 60.9%,
follow up: 9.8% difference: -51.1%
Complication: n = 3 (7.0%)
Re-operation: n = 1 (2.3%)
Prodisc

Bertagnoli
et al. [27]
Indication/Diagnosis:
Degenerative disc disease (DDD) (n = 67)
Failed disc surgery syndrome (n = 35)
Transition zone syndrome (TZS) (n = 6)
Exclusion criteria:
Severe osteoporosis, physiological dysfunction, history of
previous infection, severe posterior element pathologies,
fracture of the vertebra, tumor.
N = 108 $50 #58
mean 42 years (range
34–65 years)
Type: ProDisc II

Level:
1-level L5/S1 (n = 61)
L5/L6 (n = 3)
L4/L5 (n = 31)
L3/L4 (n = 7)
L2/L3 (n = 3)
2-level L4/L5/S1
(n = 10)
L2/L3 and L4/L5
(n = 1)
3-level L3/L4/L5/S1
(n = 2)
Follow up: range 3 months–2 years
lost of follow up not mentioned exact, at
least 50% lost to follow up at 1 year
Return to work: same level 64.8% (n = 35),
lower level 31.5% (n = 17), unable 3.7%
(n = 2)
Resume daily activity: average 2.3 wk (range
1.5–3.2 wk)
Overall: excellent 90.8% (n = 98), good
7.4% (n = 8), fair 1.8% (n = 2), poor 0%
(n = 0)
Complication: n = 1 (1.0%)
Re-operations: n = 0
Tropiano et al.
[28]
Indication/Diagnosis:
DDD, sympthomatic (n = 33)
Failed spine surgery (n = 20)
Inclusion criteria
Failed C 6 months of conservative treatment
Exclusion criteria
Associated facet degeneration, history of abdominal or
retroperitoneal surgery near planned anterior approach,
osteoporosis, osteopenia, structural spinal deformities,
absence (postoperative) of posterior elements, chronic
disease of major organ system, history of local infection,
pregnancy
N = 53 $35 #18
mean 45 years (range
28–68 years)
Type: ProDisc II

Level:
1-level L5/S1 (n = 27),
L4/L5 (n = 13),
2-level L4/L5/S1
(n = 9)
L3/L4/L5 (n = 2)
3-level L3/L4/L5/S1
(n = 2)
Follow up: mean 1.4 years (range 1–2 years)
lost to follow up not mentioned
Pain lumbar (VAS): pre-op: 74 (SD 25),
follow up: 13 (SD18), difference: -61
Pain radicular (VAS): pre-op: 67 (SD 30),
follow up: 19 (SD26), difference: -48
Functional status (ODI): pre-op: 56% (SD
8.2), follow up: 14% (SD 7.4), difference:
-42%
Return to work: ‘‘normal’’: 71.7%, ‘‘slightly
limited’’: 28.3%, ‘‘impossible’’: 13.2%
Patient Satisfaction: ‘‘entirely satisﬁed’’:
86.8%, ‘‘satisﬁed’’: 13.2%, ‘‘not satisﬁed’’:
0%
Complication: n = 5 (9.4%)
Re-operations: n = 3 (5.7%)
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Study/author Indicationin/exclusion criteria Demografy/type of disc
for TDR/Level of
intervention
Follow up: duration and outcome
Tropiano et al.
[29]
Indication/Diagnosis:
DDD, symptomatic
Inclusion criteria:
Single- and multi-level symptomatic DDD conﬁrmed by
radiology, severe lumbar pain, failed C 6 months of
conservative treatment
Exclusion criteria:
Facet arthrosis, central or lateral recess stenosis, osteoporosis,
sagittal or coronal plane deformity, postoperative absence of
posterior elements, sequestrated herniated nucleus pulposis
N = 55 $25 #30
mean 46 years (range
25–65 years)
Type: ProDisc I

Level:
1-level L5/S1 (n = 10),
L4/L5 (n = 17),
L4/L5* (n = 6),
L3/L4 (n = 2)
2-level L3/L4/L5
(n = 1)
L3/L4/L5* (n = 1)
L4/L5/S1 (n = 15)
3-level L3/L4/L5/S1
(n = 3)
*with concomitant L5–
S1 arthrodes
Follow up: mean 104 months (range 84–128
months)
14.1% lost to follow up (n = 64 originally
included)
Low-back pain (severe or moderate) pre-op:
94.5%, follow-up: 43.6%, difference:
-50.9%
Lower-limb pain (severe or moderate) pre-
op: 85.5%, follow-up: 21.8%, difference:
-63.7%
Impairment (substantially or limited or
impossible)
pre-op: 83.6%, follow-up: 20.0%, difference:
-63.6%
Functional status, Modiﬁed Stauffer-
Coventry score (scale 0–20)
pre-op: 7.0 (SD 3.3), follow up: 16.1 (SD
2.8), difference: ±9.1
Patient Satisfaction: ‘‘completely satisﬁed’’
63.6%, ‘‘satisﬁed’’ 27.3%, ‘‘not satisﬁed’’
9.0%
Overall: excellent 60%, good 14.5%, poor
25.5%
Complications: n = 10 (18.2%)
Re-operations: n = 3 (5.5%)
Bertagnoli
et al. [30]
Indication/Diagnosis:
Single-level DDD, symptomatic
Inclusion criteria:
Single-level symptomatic DDD at L3–S1 conﬁrmed by
radiology, back and/or leg (radicular) pain, failed C 9
months of conservative treatment, age between 18 and
60 years
Exclusion criteria:
patients with spinal stenosis, osteoporosis, prior fusion
surgery, chronic infections, metal allergies, pregnancy, facet
arthrosis, inadequate vertebral endplate size, more than one
level of spondylosis, neuromuscular disease, Worker’s
Compensation, spinal litigation, body mass index greater
than 35, and/or any isthmic or degenerative
spondylolisthesis greater than Grade 1
N = 104 $57 #47
median 48 years (range
36–60 years)
Type: ProDisc II

Level:
1-level L5/S1 (n = 80),
L4/L5 (n = 17)
L3/L4 (n = 7)
Follow up: 24 months (6 weeks, 3, 6, 12,
24 months),
12% lost to follow up (n = 118 originally
included)
Pain (VAS): pre-op: 75, follow up: 30,
difference: -45
Back Pain:
No pain: pre-op: 0%, follow up: 32.0%,
difference: ?32.0%
Occasional pain: pre-op: 15.3%, follow up:
59.2%, difference: ?43.9%
Regular pain: pre-op: 84.6%, follow up:
9.0%, difference: -75.6%
Radiculair Pain:
No pain: pre-op: 11.9%, follow up: 62.6%,
difference: ?50.7%
Occasional pain: pre-op: 45.5%, follow up:
29.5%, difference: -16.0%
Regular pain: pre-op: 42.6%, follow up:
8.8%, difference: -33.8%
Functional status (ODI): pre-op: 54% follow
up: 29%, difference: -25%
Return to work: Full-time: threefold increase,
Part-time: fourfold increase, not working:
ﬁvefold decrease
Patient Satisfactory: ‘‘completely satisﬁed’’
58.3%, ‘‘satisﬁed’’ 38.8%, ‘‘unsatisﬁed’’
3.1%
Complication: n = 5 (4.2%)
Re-operations: n = 1 (1.0%)
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Study/author Indicationin/exclusion criteria Demografy/type of disc
for TDR/Level of
intervention
Follow up: duration and outcome
Bertagnoli
et al. [31]
Indication/Diagnosis:
Multi-level DDD, symptomatic
Inclusion criteria:
Multi-level symptomatic DDD at L1–S1 conﬁrmed by
radiology, back and/or leg (radicular) pain, failed C 9
months of conservative treatment, age between 18 and
60 years
Exclusion criteria:
Patients with spinal stenosis, osteoporosis, prior fusion
surgery, chronic infections, metal allergies, pregnancy, facet
arthrosis, inadequate vertebral endplate size, more than one
level of spondylosis, neuromuscular disease, Worker’s
Compensation, spinal litigation, body mass index greater
than 35, and/or any isthmic or degenerative
spondylolisthesis greater than Grade 1
N = 25 $10 #15
median 51 years (range
30–60 years)
Type: ProDisc II

Level:
2-level L2/L3 and L4/
L5 (n = 1) L3/L4 and
L5/S1 (n = 1)
L3/L4/L5 (n = 5)
L4/L5/S1 (n = 8)
3-level L3/L4/L5/S1
(n = 10)
Follow up: 24 months (6 weeks, 3, 6, 12,
24 months),
13.8% lost to follow up (n = 29 originally
included)
Pain (VAS): pre-op: 83 (60–100), follow up:
21 (0–60), difference: -62
Back Pain:
No pain: pre-op: 0%, follow up: 56%,
difference: ?56%
Episodic pain: pre-op: 8%, follow up: 36%,
difference: ?28%
Regular pain: pre-op: 92%, follow up: 8%,
difference: -84%
Radiculair Pain:
No pain: pre-op: 20%, follow up: 67%,
difference: ?47%
Episodic pain: pre-op: 28%, follow up: 33%,
difference: ?5%
Regular pain: pre-op: 52%, follow up: 0%,
difference: -52%
Functional status (ODI): pre-op: 65.0% (42–
92) follow up: 21.6% (0–48), difference:
-43.4%
Return to work: Full-time: ﬁvefold increase,
Part-time: twofold increase, not working:
fourfold decrease
Patient Satisfactory: ‘‘completely satisﬁed’’:
75%, ‘‘satisﬁed’’: 17%, ‘‘unsatisﬁed’’: 8%
Complication: n = 5 (20%)
Re-operations: n = 1 (4.0%)
Chung et al.
[32]
Indication/Diagnosis:
DDD, symptomatic
Inclusion criteria
symptomatic DDD at L3–S1 conﬁrmed by radiology, primary
complaint of back pain, failed C 6 months of conservative
treatment, age between 18 and 60 years, minimum disc
height of 4 mm, ODI C 40
Exclusion criteria
scoliosis, spondylolysis, spondylolithesis, severe facet
degeneration, osteoporosis
N = 36 $20 #16
mean 43 years (range
25–58 years)
Type: ProDisc II

Level:
1-level: (n = 25)
2-level: (n = 11)
L5/S1 (n = 21),
L4/L5 (n = 24)
L3/L4 (n = 2)
Follow up: 24 months (6 weeks, 12,
24 months),
5.3% lost to follow up (n = 38 originally
included)
Low back pain (VAS): pre-op: 75, follow up:
30, difference: -45
Leg pain (VAS): pre-op: 47, follow up: 12,
difference: -35
Functional status (ODI): pre-op: 69.2%,
follow up: 21.0%, difference: -48.2%
Clinical success (ODI improvement[25%):
94.4% (n = 34)
Clinical success (ODI improvement[75%):
44.4% (n = 16)
Complication: n = 5 (13.8%)
Re-operations: n = 0
Siepe et al.
[33, 34],
Mayer et al.
[36]
Indication/Diagnosis:
DDD, symptomatic
Inclusion criteria
Symptomatic DDD conﬁrmed by radiology, primary
complaint of low back pain, failed conservative treatment
Exclusion criteria
DDD ? disc herniation, post-discectomy, DDD ? modic
changes, central or lateral spinal stenosis, facet joint
arthrosis/symptomatic facet joint problems, spondylolysis/
spondylolisthesis, spinal instability (iatrogenic/altered
posterior elements, e.g., following, laminectomy), major
deformity/curvature deviations (e.g., scoliosis), metabolic
bone disease (e.g., manifest osteoporosis/osteomalacia),
previous operation with severe scarring and radiculopathy,
compromised vertebral body (irregular endplate shape),
previous/latent infection, metal allergy, spinal tumor, post-
traumatic segments
N = 99 $60 #39
mean 43 years (range
22–66 years)
Type: ProDisc II

Level:
1-level L5/S1 (n = 57),
L4/L5 (n = 22),
2-level L4/L5/S1
(n = 20)
Follow up: 12 months (3 m, 6 m, 12 m),
0% lost to follow up (n = 218 included, 99
had reached 12 months FU)
pain (VAS): pre-op: 70, follow up: 30,
difference: -40 (SD 24)
Functional status (ODI): pre-op: 42.0%,
follow up: 21.0%, difference: -21.0% (SD
17)
Return to work: 66.3%
Patient Satisfaction: ‘‘completely satisﬁed’’
58.5%, ‘‘satisﬁed’’ 20.2%, ‘‘unsatisﬁed’’
21.3%
Complication: n = 17 (17.2%)
Re-operations: n = 8 (8.1%)
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the BAK cage at the 2-year follow up, and there is very low
quality evidence (based on 1 study only with a high risk of
bias) that there are no clinical relevant differences on the
primary outcome measures at the 5-year follow up.
ProDisc
 trial (Table 1) The ProDisc trial [52], which
had a high risk of bias, randomized 236 patients to either
TDR with the ProDisc device (n = 161) or to anterior
lumbar circumferential fusion (using femoral ring allograft
and posterolateral fusion with autogenous iliac crest bone
graft in combination with pedicle screws) (n = 75). Out-
comes were reported with 2-year follow-up. Clinical suc-
cess was deﬁned using a combination of 10 outcomes as
required by the FDA (Oswestry C 15 points, SF-36
improvement, device success, neurologic success and six
radiographic outcomes: no migration, no subsidence, no
radiolucency, no loss of disc height, fusion status and
ROM). Clinical success was statistically signiﬁcantly better
in the ProDisc (54.3%) than the fusion group (40.8%)
Table 3 continued
Study/author Indicationin/exclusion criteria Demografy/type of disc
for TDR/Level of
intervention
Follow up: duration and outcome
Ogon et al.
[35]
Indication/Diagnosis:
degenerative disc disease (DDD)
Exclusion criteria
spondylarthrosis, spondylolisthesis, spinal stenosis, scoliosis,
osteoporosis, infection, tumor
N = 34 $26 #8
mean 44 years (range
30–60 years)
Type: ProDisc

Level:
1-level L5/S1 (n = 22),
L4/L5 (n = 10),
2-level L4/L5/S1
(n = 2)
Follow up: 12 months (3 m, 12 m),
lost to follow up not mentioned
pain (VAS): pre-op: 74, follow up: 28,
difference: -46
Functional status (ODI): pre-op: 48.0%,
follow up: 13.1%, difference: -34.9%
Functional status (SF-36)
PCSS: pre-op: 31.3, follow up: 44.2,
difference: -10.9
MCSS: pre-op: 38.6, follow up: 44.8,
difference: -6.2
Patient Satisfaction: ‘‘completely satisﬁed’’:
76.5%, ‘‘satisﬁed’’: 14.7%, ‘‘unsatisﬁed’’:
8.8%
Complication: n = 4 (11.8%)
Re-operations: n = 1 (2.9%)
Maverick

Huec et al.
[37–39]
Indication/Diagnosis:
DDD, symptomatic
Inclusion criteria:
symptomatic DDD conﬁrmed by radiography and MRI,
predominant chronic back pain and absence of permanent
nerve root compression, failed C 12 months of conservative
treatment, ODI[30%, age between 20 and 60 years
irrespective of sex
Exclusion criteria:
Severe osteoporosis, physiological dysfunction, history of
previous infection, severe posterior element pathologies,
fracture of the vertebra, tumor.
N = 64 $39 #25
mean 44 years (range
37–51 years)
Intervention: TDR
TDR ?fusion
Type: Maverick

Level:
1-level: L5/S1 (n = 35),
L4/L5 (n = 14),
L3/L4 (n = 2)
2-level:L5/S1 TDR ?
L5/S1 fusion (n = 13)
Follow up: 24 months (1 m, 3 m, 6 m, 12 m,
24 m),
0% lost to follow up
Low back pain (VAS): pre-op: 76 (SD17),
follow up: 32 (SD18), difference: -44,
Leg pain (VAS): pre-op: 39, follow up: 21,
difference: -18
Functional status (ODI): pre-op: 43.8%
follow up: 23.1%, difference: -20.7%
Clinical success (ODI improvement[25%):
75%
Complication: n = 26 (40.6%)
Reoperation: n = 0 (0%)
Acroﬂex

Fraser et al.
[40]
Indication/Diagnosis:
DDD, sympthomatic
Inclusion criteria:
1-level or 2-level symptomatic DDD at L4-S1 conﬁrmed by
radiology, back and/or leg (radicular) pain, failed C 6m oo f
conservative treatment, age between 30 and 55 years
Exclusion criteria:
previous lumbar surgery with the exception of discectomy and
chemonucleolysis at the target level, steep lumbosacral
angle at the target, central or lateral spinal stenosis,
spondylolisthesis, systemic disease that would impact the
patient’s condition, obesity, alcohol and/or drug abuse,
presence of three or more positive Waddell signs, scoliosis,
major psychiatric disorder,current involvement in litigation
related to the spinal condition or involvement in pursuing
legal action related to the spinal condition
N = 28 $14 #14
mean 41 years (range
30–54 years)
Type: Acroﬂex

Level:
1-level L5/S1 (n = 19),
L4/L5 (n = 5),
2-level:L4/L5/S1
(n = 4)
Follow up: 24 months (6, 12 weeks, 6, 12,
24 months),
lost to follow up not mentioned
Low back pain (LBOS): pre-op: 17.7, follow
up: 33.0, difference: -15.3
Functional status (ODI): pre-op: 49.3%
follow up: 34.4%, difference: -14.9%
Complication: n = 17 (60.7%)
Re-operation: n = 8 (28.6%)
VAS (scale 0–100), ODI (scale 0–100)
All ODI scores and VAS scores were converted into 0–100 scale
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123(P\0.05). Although this trail was designed as a non-
inferiority study, it is unclear what statistical testing is
applied. However, there were no signiﬁcant differences
between both groups on the mean functional impairment
(-28.9 vs. -22.9%) and pain intensity scores (-39 vs.
-32). In conclusion, there is very low quality evidence
(based on 1 study only with a high risk of bias and
inconsistent ﬁndings) for contradictory results on the pri-
mary outcome measures at the 2-year follow up for the
ProDisc when compared with anterior lumbar circumfer-
ential fusion.
Flexicore
 trial (Table 1) The Flexicore trial [53], with a
high risk of bias reported the initial results of 76 patients
from two clinics involved in a randomized multicentre
controlled trial comparing the Flexicore device (n = 44)
versus anterior lumbar circumferential fusion (n = 23)
with 2 year follow-up. These 76 patients are only a small
proportion of all randomized patients (n = 401) included
in the complete trail. Overall, dropout rate was high, 33
patients (75%) in the intervention group and 16 patients
(70%) in the control group after two years. Improvement in
pain intensity (VAS -70 vs. -62) and functional impair-
ment (Oswestry -56 vs. -46%) was slightly better in the
Flexicore group than in the fusion group, but the authors
did not report whether this difference was statistically
signiﬁcant or not. Because these are preliminary results, in
addition to the high risk of bias, we refrain from drawing
conclusions based on this study. In general, these results
suggest no clinical relevant differences between TDR
surgery and fusion techniques and a small overall success
rate in both groups (approximately 50%).
(3) What is the safety of total disc replacement surgery?
Although some studies reported no major complications,
other cohort studies describe a wide range (1.0–91.0%) of
complication rates following TDR. The majority of these
studies reported complication rates ranging from 10 to
40%. Complications can be separated into those related to
the surgical approach (e.g. vascular injury, nerve root
damage, retrograde ejaculation) range from 2.1 to 18.7%,
related to the prosthesis (e.g. subsidence, migration,
implant displacement, implant failure, end plate fracture)
range from 2.0 to 39.3% and related to the treatment (e.g.
wound, pain, neuromusculoskeletal) range from 1.9 to
62.0%. General surgical related complications ranged from
1.0 to 14.0%. Reoperation at index level was seen in 1.0–
28.6% (Table 4). These reported complication rates and
reoperation rates have to be interpreted carefully, because
they have been described poorly.
Below we will describe the complications rates and re-
operation rates as found in the three trials. The Flexicore
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123trial [53] report 22.7% complications in the TDR group and
43.5% in the fusion group. Reoperations are reported in
both groups; 11.4% for TDR and 26.1% for fusion
(Table 5).
In the Charite ´ trial, overall complication rates published
by Blumenthal et al. [10] were 29.1% for TDR and 50.2%
for fusion at 2-year follow-up. Device failures necessitating
reoperation were reported in 5.4% of patients in de TDR
group and 9.1% of patients in the fusion group at 2 year
follow-up (Table 5). However, in the FDA report on the
Charite ´ trial much higher scores of adverse effects (TDR
group 181.9% and fusion group 189.6%) were reported
[56]. In an article from McAfee et al. [57], analysing the
incidence of reoperations, even higher reoperation rates in
the Charite ´ trial are reported (6.3% in de TDR group and
10.1% in the fusion group).
In the ProDisc trial, there was a similar discrepancy
between the article and the FDA report. The overall com-
plication rate as reported by Zigler et al. [52] were 7.3%
and 6.3% for TDR and fusion, respectively, but in the FDA
report on the ProDisc trial much higher scores on adverse
events were reported (TDR group 255.5% and fusion group
270.7%) [58]. Reoperation was necessary for 3.7% TDR
patients and 5.4% fusion patients according to Zigler et al.
The number of patients needed a reoperation was similar in
the FDA report; however, the included number of patients
in the trial was higher so the percentage of reoperation in
the FDA rapport was slightly higher (Table 5).
Geisler et al. [59] analysed only the neurological com-
plications in the Charite ´ trial. The incidence was no higher
in patients with the Charite ´ (16.6%) than patients with
BAK fusion (17.2%) (P[0.3). Major neurologic compli-
cations in the Charite ´ group (e.g. burning or dysesthetic leg
pain, motor deﬁcit in index level, nerve root injury) were
reported in 4.9% and in the fusion group (e.g. burning or
dysesthetic leg pain, motor deﬁcit at the index level) in 4%.
One device related major complication, nerve root injury,
was reported in the TDR group.
Leary et al. [60] reported on 18 patients requiring an
anterior revision procedure for repositioning or removal of
the Charite ´ prosthesis because of complications. Three
patients required revision of two levels. One patient had
both levels revised in a single procedure, whereas two
patients required staged procedures in order to revise both
implants. Therefore, 21 implants were revised via 20
anterior procedures in 18 patients. Six revision cases were
performed within the early postoperative period (7–
14 days), all as a result of implant migration or dislocation.
Late revision cases were required in 14 cases (range
3 weeks–4 years) due to implant migration, dislocation,
end plate fractures, subsidence or persistent low back pain.
Van Ooij et al. [61–65] reported in several publications
patients following implantation of the Charite ´ prosthesis
who experienced complications. Over the last 10 years, 75
patients with persisting back and leg pain and being
unsatisﬁed with their clinical condition have been seen and
analysed. An overview on late complications after TDR:
subsidence (n = 39), prosthesis too small (n = 24), adja-
cent disc degeneration (n = 36), degenerative scoliosis
(n = 11), facet joint degeneration on CT scan (n = 25),
anterior migration (n = 6), posterior migration (n = 2),
breakage metal wire (n = 10), wear (n = 5), severe oste-
olysis (n = 1), subluxation PE core (n = 1). 46 out of
these 75 needed one or more salvage operations after their
TDR. Fifteen patients were receiving posterior fusion
without removal of the prosthesis. Because of persisting
pain, afterwards 4 patients had their prosthesis removed in
an additional operation. In 22 patients, 26 prostheses were
removed and an anterior and posterior fusion was per-
formed. In addition, seven patients received posterior
Table 5 Overview complications trials
Prodisc
 Charite ´
 FlexiCore

Index (n = 162),
82 #
Control (n = 80),
34 #
Index (n = 205),
113 #
Control (n = 99),
44 #
Index
(n = 44)
Control
(n = 23)
Approach-related 2 (2.4%)
a 2 (2.5%) 16 (9.1%)
a 9 (12.8%)
a 1 (2.3%) 0
Prosthesis related 5 (3.1%) 0 8 (3.9%) 10 (10.1%) 2 (4.5%) 0
Treatment related 1 (0.6%) 0 17 (8.3%) 23 (23.2%) 5 (11.4%) 8 (34.8%)
General surgical
related
2 (1.2%) 3 (3.8%) 16 (7.8%) 4 (4.0%) 2 (4.5%) 2 (8.7%)
Total of complications 10 (7.3%) 5 (6.3%) 57 (29.1%) 46 (50.2%) 10 (22.7%) 10 (43.5%)
Reoperation at index
level
6 (3.7%) 4 (5.4%) 11 (5.4%) 9 (9.1%) 5 (11.4%) 6 (26.1%)
13 (6.3%) 10 (10.1%)
Table based on the published manuscripts, number of compilation in FDA report [56, 58] deviated (see text)
a Retrograde ejaculation calculated for men only
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123fusion elsewhere, and in two patients, the disc prosthesis
was removed elsewhere. Intraoperatively, the surgeon
encountered three times vessel damage. In conclusion, a
wide range of complications rates following TDR (1–
90.0%) was found in all cohort studies. The majority of the
studies reported complication rates ranging from 10 to
40%. Reoperation at index level was reported in 1.0–
28.6%. The three randomized controlled trials published
overall complication rates range from 7.2 to 28.6% in the
TDR group and 6.7 to 50.2% in the fusion group. The
overall reoperation rate at the index level ranged from 3.7
to 11.4% in the TDR group and 5.4–26.1% in the fusion
group. However, much higher rates were reported in FDA
reports on the Charite ´ and ProDisc trials.
Discussion
In this article, we systematically reviewed the available
literature on the clinical course, effectiveness, cost-effec-
tiveness, and safety of TDR in patients with symptomatic
DDD. Sixteen prospective cohort studies were identiﬁed
that assessed the course of complaints and symptoms.
These studies suggest pain relief, improvement in func-
tional status and patient satisfaction after TDR. However,
the quality of reporting on outcomes was often poor,
hampering an adequate interpretation. In addition, a sig-
niﬁcant amount of complications was reported. These
cohort studies lacked control group, which is necessary to
evaluate effectiveness of TDR. Only three randomized
controlled multicentre trials were identiﬁed that had
assessed the effectiveness of TDR. The results show that
there is low quality evidence (based on one study only with
a low risk of bias) that there are no clinically relevant
differences on the primary outcome measures between the
Charite ´ group and the BAK cage at 2 years follow up, and
there is very low quality evidence (based on 1 study only
with a high risk of bias) that there are no clinically relevant
differences on the primary outcome measures at 5 years
follow up. Furthermore, there is very low quality evidence
(based on one study only with a high risk of bias) for
contradictory results on the primary outcome measures for
the ProDisc when compared with anterior lumbar circum-
ferential fusion at the 2-year follow up. There is insufﬁ-
cient evidence on the Flexicore, because this trial had a
high risk of bias, and should be considered as a preliminary
report because it only reported on a small proportion of all
included patients who participated in this multi centre trial.
For assessing the complication rate, all reported com-
plications were extracted from the cohort studies and ran-
domized controlled trials included in this review, as well as
overview studies on complication rates. A wide range of
complications rates following TDR (1–91.0%) was found
in the cohort studies. The majority of the studies reported
complication rates ranging from 10 to 40%. Reoperation at
the index level was reported in 1.0–28.6%. In the three
randomized controlled trials, overall complication rates
ranged from 7.3 to 29.1% in the TDR group and from 6.3
to 50.2% in the fusion group. The overall reoperation rate
at the index level ranged from 3.7 to 11.4% in the TDR
group and from 5.4 to 26.1% in the fusion group. However,
much higher rates were reported in FDA reports on the
Charite ´ and ProDisc trials. No full economic evaluation
was identiﬁed, so there is no evidence regarding the cost-
effectiveness of TDR.
The course of DDD complaints and/or symptoms
following total disc replacement surgery
We identiﬁed 16 prospective cohort studies to evaluate the
course of DDD complaints and/or symptoms. The outcome
results suggested a positive course after TDR with a high
proportion of patients satisﬁed with the result. However,
these studies were of poor methodological quality and
detailed information on how outcomes were measured was
often lacking. For example, it was often unclear which
criteria were used for clinical success and how return to
work was measured. Furthermore, another drawback is that
a signiﬁcant amount of complications was reported as well.
Moreover, these results have to be interpreted in light of
controversy and limited literature regarding the causal
relationship between DDD and chronic low back pain [4].
Boden et al. [66] reported on 67 asymptomatic individuals
assessed for DDD with MRI. DDD was seen in 34% of the
individuals between 20 and 39 years of age; 59% of indi-
viduals between 40 and 59 years of age, and in all but one
(93%) between 60 and 80 years of age. Jensen et al. [67]
reported on 98 asymptomatic people after MRI and con-
cluded that 64% of these people had an intervertebral disc
abnormality. This challenges the rationale of surgery for
DDD in the absence of convincing pathological pathways
of DDD.
The effectiveness of total disc replacement surgery
compared to other treatments
The Flexicore trial should be interpreted with great caution
because of the high risk of bias. Of the three randomized
controlled trials, the 2-year follow up of the Charite ´ trial
was considered to have a low risk of bias. However, the
fusion technique with BAK cages and the iliac crest bone
autograft used in this trial are techniques that are no longer
commonly used because of poor outcomes [68–70]. A
better comparator would be the circumferential fusion
technique which was used in the ProDisc and Flexicore
trials. The use of autograft in all three studies may also be
1276 Eur Spine J (2010) 19:1262–1280
123criticized as many surgeons now use both recombinant
BMP-2 and/or percutaneous pedicle screw ﬁxation when
performing lumbar fusion [55]. Use of an inadequate
control intervention brings into question the clinical rele-
vance of the results of the three trials. An additional con-
cern is the fact that the literature is still controversial about
the superiority of fusion compared to conservative treat-
ment [5, 15, 71, 72]. For this reason, it can be interesting to
compare the effectiveness of TDR to conservative treat-
ment. At present, no studies comparing total disc replace-
ment surgery to other treatments have been published.
The three randomized controlled trials selected patients
carefully, scrutinizing various contraindications for TDR.
Because of this careful selection, the published trials do
not provide evidence for the widespread use of TDR in all
patients with DDD. The relevance of the clinical out-
comes in the Charite ´ and the ProDisc trials can also be
challenged. First, modest success rates were observed in
both the TDR and the fusion groups. In the Charite ´ trial,
only 57.1% of patients with TDR met all 4 criteria for
success, when compared with 46.5% in the fusion group
(P\0.0001). In the ProDisc group, only 53.4% of
patients with TDR met all 10 FDA criteria for success,
when compared with 40.8% in the fusion group
(P = 0.0438). Second, in the Prodisc trial, 69.1% of TDR
subjects improved by more than 25% on the Oswestry,
when compared with 54.9% in the fusion group. In the
Charite ´ trial, 63.9% of TDR subjects improved by more
than 25% on the Oswestry, compared to 50.5% in the
fusion group. The use of the 25% benchmark for
improvement should be interpreted against a background
of a recently published consensus statement that advo-
cates a 30% improvement in Oswestry as a benchmark for
clinically relevant improvement. This recommendation
focussed primarily on conservative interventions in a
primary care setting. It was suggested that it might be
more appropriate to use larger change scores as bench-
marks for expensive and risky procedures [73]. Third, one
of the purposes of the device implementation is to reduce
low back pain whereas the deﬁnition of success did not
consider pain relief or opioid use. Finally, Oswestry and
VAS cannot discriminate between pain that is residual
from the iliac crest after fusion surgery versus the lumbar
spine. Therefore, Oswestry and VAS may be artiﬁcially
higher in the fusion group compared with TDR.
The ODI was used in all included RCT’s, but different
versions of the ODI were used. Sasso used ODIv2.0 [53].
Blumenthal used the ODIv1.0 and Zigler used the ODI
(chiropractic revised version [74]) [75]. Because different
versions of the ODI are used, a direct comparison between
studies is hampered. Zigler, however, holds the opinion
that the differences between the various ODI versions are
subtle and, they think, inconsequential [77].
Davidson [77] and Fairbanks [75] hold the opinion that
the amendments of this ‘chiropractic revised version’ are
major and therefore this version cannot be compared with
the ofﬁcial versions of ODI.
The safety of the total disc replacement surgery
Complications have been poorly described in the pro-
spective cohort studies and the randomized controlled tri-
als. It is interesting that the complications rates and
reoperation rates are lower in the published articles than in
the FDA reports [56, 58]. This illustrates the complexity of
reporting on adverse effects. Compared to the journals
where the papers were published, apparently the FDA
requires exhaustive and detailed reporting of ‘‘adverse
events’’ most of which have no relationship to the success
or failure of the prosthesis. Complications associated with
lumbar fusion include incomplete relief of pain, loss of
motion, loss of sagittal balance, pseudoarthrosis, adjacent
segment degeneration, and bonegraft donor site complica-
tion. However, a separate set of concerns exist in TDR.
Wear debris leading to osteolysis and systematic effects,
vertebral body damage, posterior migration or extrusion
may lead to device failure and serious vascular complica-
tions. Prosthesis that fail to adequately replicate the phys-
iologic kinematics of the lumbar spine may predispose the
patient to facet joint degeneration. Without true motion
preservation, the devices will merely act as interbody
spacers with no potential to prevent adjacent level degen-
eration [78]. Finally, reported complications for TDR show
there can be severe and even life threatening, e.g. major
vascular injury, major nerve root damage and device fail-
ure. However, these complication rates are low [9, 17, 79,
80].
Furthermore, in the two low risks of bias studies [10,
52], the re-operation rates in the TDR group are slightly
higher than in the fusion group. However, this has to be
balanced against the fact that re-operation procedures for
TDR are more complex.
The use of intervertebral disc prostheses as an alterna-
tive to spinal fusion has been advocated to preserve seg-
mental motion and to prevent adjacent degeneration.
However, there is no consensus on this subject in literature.
Some studies suggest adjacent level degeneration is pre-
vented after TDR [6, 12]. However, other studies show
adjacent disc degeneration after TDR [61, 81]. This could
be the result of the DDD itself, spreading to multiple levels
of the spine, and/or be a consequence of stresses on adja-
cent levels, generated from unphysiological motion and
functioning of the disc prosthesis [61]. Moreover, there is
little knowledge regarding complications on the long term.
Putzier et al. [81] published a retrospective study with
17 years follow-up and reoperation was necessary in 11%
Eur Spine J (2010) 19:1262–1280 1277
123of patients. It is important to know more about long-term
complications because most operated patients are of rela-
tively young age, between 30 and 50 years. A disc pros-
thesis used for TDR should survive for at least 40 years. It
is very questionable if the lifetime of the designs now
available will be that long as little is known about long-
term behaviour of biomaterials in the spine. We do know
that revision surgery can be dangerous because of adher-
ence to great vessels and the nerve plexus. Studies that
review long-term complications and longevity of the
prostheses are highly recommended.
Conclusion
There is low quality evidence that there are no clinically
relevant differences on the primary outcome measures
between the Charite ´ group and the BAK cage at 2 years
follow up, and there is very low quality evidence that there
are no clinical relevant differences on the primary outcome
measures at 5 years follow up. For the ProDisc device, there
is very low quality evidence for contradictory results on the
primary outcome measures when compared with anterior
lumbar circumferential fusion. Furthermore, reported com-
plicationratesvariedfrom1.0to91.0%incohortstudiesand
7.3to29.1%inrandomizedcontrolledtrials.Stilllackingare
high quality prospective, controlled, long-term follow-up
studies, including a full economic evaluation taking into
account all relevant cost when compared with the clinical
beneﬁt, and with relevant control groups to establish the
efﬁciency and the longevity of the devices. The existing
evidence, speciﬁcally regarding long-term effectiveness
and/or safety is considered insufﬁcient to justify the wide-
spread use of TDR over fusion for single level degenerative
disc. Itis recommended that disc replacement surgery at this
time only is performed within prospective scientiﬁc studies
until further documentation of its efﬁciency is provided.
Acknowledgments Forthisreview,theauthorsreceivedagrantfrom
The Health Care Insurance Board (CVZ), Diemen, The Netherlands.
Conﬂict of interest statement For this review, the authors received
a Grant from The Health Care Insurance Board (CVZ), Dieman,
The Netherlands.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Van Tulder MW, Koes BW, Bouter LM (1995) A cost-of-illness
study of back pain in The Netherlands. Pain 1995:233–240
2. Pengel LHM, Herbert RD, Maher CG et al (2003) Acute low back
pain: systematic review of its prognosis. BMJ 327:323
3. Errico TJ (2005) Lumbar disc arthroplasty. Clin Orthop Relat Res
435:106–117
4. Frelinghuysen P, Huang RC, Girardi FP et al (2005) Lumbar total
disc replacement part I: rationale, biomechanics, and implant
types. Orthop Clin North Am 36:293–299
5. Fritzell P, Hagg O, Wessberg P et al (2001) Lumbar fusion versus
nonsurgical treatment for chronic low back pain: a multicenter
randomized controlled trial from the Swedish Lumbar Spine
Study Group. Spine 26:2521–2532
6. Hochschuler SH, Ohnmeiss DD, Guyer RD et al (2002) Artiﬁcial
disc: preliminary results of a prospective study in the United
States. Eur Spine J 2:S106–S110
7. Errico TJ (2004) Why a mechanical disc? Spine J 4:151S–
157S
8. Freeman BJC, Davenport J (2006) Total disc replacement in the
lumbar spine: a systematic review of the literature. Eur Spine J
15(Suppl 3):S439–S447
9. de Kleuver M, Oner FC, Jacobs WC (2003) Total disc replace-
ment for chronic low back pain: background and a systematic
review of the literature. Eur Spine J 12:S108–S116
10. Blumenthal S, McAfee PC, Guyer RD et al (2005) A prospective,
randomized, multicenter Food and Drug Administration investi-
gational device exemptions study of lumbar total disc replace-
ment with the CHARITE artiﬁcial disc versus lumbar fusion: part
I: evaluation of clinical outcomes. Spine 30:1565–1575
11. Cunningham BW, Dmitriev AE, Hu N et al (2003) General
principles of total disc replacement arthroplasty: seventeen cases
in a nonhuman primate model. Spine 28:S118–S124
12. Link HD (2002) History, design and biomechanics of the LINK
SB Charite artiﬁcial disc. Eur Spine J 11:S98–S105
13. McAfee PC, Cunningham B, Holsapple G et al (2005) A pro-
spective, randomized, multicenter Food and Drug Administration
investigational device exemption study of lumbar total disc
replacement with the CHARITE artiﬁcial disc versus lumbar
fusion: part II: evaluation of radiographic outcomes and corre-
lation of surgical technique accuracy with clinical outcomes.
Spine 30:1576–1583
14. Szpalski M, Gunzburg R, Mayer M (2002) Spine arthroplasty: a
historical review. Eur Spine J 11(Suppl 2):S65–S84
15. Fairbank J, Frost H, Wilson-MacDonald J et al (2005) Ran-
domised controlled trial to compare surgical stabilisation of the
lumbar spine with an intensive rehabilitation programme for
patients with chronic low back pain: the MRC spine stabilisation
trial. BMJ 330:1233
16. Fernstrom U (1966) Arthroplasty with intercorporal endoprothe-
sis in herniated disc and in painful disc. Acta Chir Scand Suppl
357:154–159
17. Randolph GB, Scioscia TN, Wang JC (2006) Lumbar total disc
arthroplasty: state of the data. Semin Spine Surg 18:61–71
18. van Tulder M, Furlan A, Bombardier C et al (2003) Updated
method guidelines for systematic reviews in the Cochrane col-
laboration back review group. Spine 28:1290–1299
19. Brozek J, Akl E, Alonso-Coello P, on behalf of the GRADE
Working Group et al (2009) Grading quality of evidence and
strength of recommendations in clinical practice guidelines.
Allergy 64:669–677
20. Lemaire JP, Skalli W, Lavaste F et al (1997) Intervertebral disc
prosthesis. Results and prospects for the year 2000. Clin Orthop
Relat Res 337:64–76
21. Zeegers WS, Bohnen LM, Laaper M et al (1999) Artiﬁcial disc
replacement with the modular type SB Charite III: 2-year results
in 50 prospectively studied patients. Eur Spine J 8:210–217
22. Regan JJ (2005) Clinical results of charite lumbar total disc
replacement. Orthop Clin North Am 36:323–340
1278 Eur Spine J (2010) 19:1262–1280
12323. Lemaire JP, Carrier H, Eh SariAli et al (2005) Clinical and
radiological outcomes with the Charite artiﬁcial disc: a 10-year
minimum follow-up. J Spinal Disord Tech 18:353–359
24. Ross R, Mirza AH, Norris HE et al (2007) Survival and clinical
outcome of SB Charite III disc replacement for back pain. J Bone
Joint Surg Br 89:785–789
25. Gioia G, Mandelli D, Randelli F (2007) The Charite III artiﬁcial
disc lumbar disc prosthesis: assessment of medium-term results.
J Orthop Traumatol 8:134–139
26. Warachit P (2008) Results of Charite artiﬁcial lumbar disc
replacement: experience in 43 Thais. J Med Assoc Thai 91:1212–
1217
27. Bertagnoli R, Kumar S (2002) Indications for full prosthetic disc
arthroplasty: a correlation of clinical outcome against a variety of
indications. Eur Spine J 11(Suppl 2):S131–S136
28. Tropiano P, Huang RC, Girardi FP et al (2003) Lumbar disc
replacement: preliminary results with ProDisc II after a minimum
follow-up period of 1 year. J Spinal Disord Tech 16:362–368
29. Tropiano P, Huang RC, Girardi FP et al (2005) Lumbar total disc
replacement. Seven to eleven-year follow-up. J Bone Joint Surg
Am 87:490–496
30. Bertagnoli R, Yue JJ, Shah RV et al (2005) The treatment of
disabling single-level lumbar discogenic low back pain with total
disc arthroplasty utilizing the Prodisc prosthesis: a prospective
study with 2-year minimum follow-up. Spine 30:2230–2236
31. Bertagnoli R, Yue JJ, Shah RV et al (2005) The treatment of
disabling multilevel lumbar discogenic low back pain with total
disc arthroplasty utilizing the ProDisc prosthesis: a prospective
study with 2-year minimum follow-up. Spine 30:2192–2199
32. Chung SS, Lee CS, Kang CS (2006) Lumbar total disc replace-
ment using ProDisc II: a prospective study with a 2-year mini-
mum follow-up. J Spinal Disord Tech 19:411–415
33. Siepe CJ, Mayer HM, Wiechert K et al (2006) Clinical results of
total lumbar disc replacement with ProDisc II: three-year results
for different indications. Spine 31:1923–1932
34. Siepe CJ, Mayer HM, Heinz-Leisenheimer M et al (2007) Total
lumbar disc replacement: different results for different levels.
Spine 32:782–790
35. Ogon M, Howanietz N, Tuschel A et al (2007) Implantation of
the Prodisc
 intervertebral disk prosthesis for the lumbar spine.
Oper Orthop Traumatol 19:209–230
36. Mayer HM, Wiechert K, Korge A et al (2002) Minimally invasive
total disc replacement: surgical technique and preliminary clini-
cal results. Eur Spine J 11(Suppl 2):S124–S130
37. Le Huec JC, Mathews H, Basso Y et al (2005) Clinical results of
Maverick lumbar total disc replacement: two-year prospective
follow-up. Orthop Clin North Am 36:315–322
38. Le Huec JC, Basso Y, Aunoble S et al (2005) Inﬂuence of facet
and posterior muscle degeneration on clinical results of lumbar
total disc replacement: two-year follow-up. J Spinal Disord Tech
18:219–223
39. Le Huec J, Basso Y, Mathews H et al (2005) The effect of single-
level, total disc arthroplasty on sagittal balance parameters: a
prospective study. Eur Spine J 14:480–486
40. Fraser RD, Ross ER, Lowery GL et al (2004) AcroFlex design
and results. Spine J 4:245S–251S
41. McAfee PC, Fedder IL, Saiedy S et al (2003) Experimental
design of total disk replacementexperience with a prospective
randomized study of the SB Charite. Spine 28:S153–S162
42. McAfee PC, Fedder IL, Saiedy S et al (2003) SB Charite disc
replacement: report of 60 prospective randomized cases in a US
center. J Spinal Disord Tech 16:424–433
43. Guyer RD, McAfee PC, Hochschuler SH et al (2004) Prospective
randomized study of the Charite artiﬁcial disc: data from two
investigational centers. Spine J 4:252S–259S
44. Blumenthal SL, Ohnmeiss DD, Guyer RD et al (2003) Prospec-
tive study evaluating total disc replacement: preliminary results.
J Spinal Disord Tech 16:450–454
45. Zigler JE (2004) Lumbar spine arthroplasty using the ProDisc II.
Spine J 4:260S–267S
46. Delamarter RB, Fribourg DM, Kanim LEA et al (2003) ProDisc
artiﬁcial total lumbar disc replacement: introduction and early
results from the United States clinical trial. Spine 28:S167–S175
47. Zigler JE (2003) Clinical results with ProDisc: European expe-
rience and U.S. investigation device exemption study. Spine
28:S163–S166
48. Zigler JE, Burd TA, Vialle EN et al (2003) Lumbar spine
arthroplasty: early results using the ProDisc II: a prospective
randomized trial of arthroplasty versus fusion. J Spinal Disord
Tech 16:352–361
49. Delamarter RB, Bae HW, Pradhan BB (2005) Clinical results of
ProDisc-II lumbar total disc replacement: report from the United
States clinical trial. Orthop Clin North Am 36:301–313
50. Auerbach JD, Wills BPD, McIntosh TC et al (2005) Lumbar disc
arthroplasty versus fusion for single-level degenerative disc dis-
ease: two-year results from a randomized prospective study. Se-
min Spine Surg 17:310–318
51. Guyer RD, McAfee PC, Banco RJ et al (2009) Prospective,
randomized, multicenter Food and Drug Administration investi-
gational device exemption study of lumbar total disc replacement
with the CHARITE artiﬁcial disc versus lumbar fusion: ﬁve-year
followup. Spine J 9:374–386
52. Zigler J, Delamarter R, Spivak JM et al (2007) Results of the
prospective, randomized, multicenter Food and Drug Adminis-
tration investigational device exemption study of the ProDisc-L
total disc replacement versus circumferential fusion for the
treatment of 1-level degenerative disc disease. Spine 32:1155–
1162
53. Sasso RC, Foulk DM, Hahn M (2008) Prospective, randomized
trial of metal-on-metal artiﬁcial lumbar disc replacement: initial
results for treatment of discogenic pain. Spine 33:123–131
54. Mayer HM, Siepe C (2007) Total lumbar disc arthroplasty. Curr
Orthop 21:17–24
55. German JW, Foley KT (2005) Disc arthroplasty in the manage-
ment of the painful lumbar motion segment. Spine 30:S60–S67
56. FDA approval Charite ´: http://www.fda.gov/cdrh/pdf4/P040006a.
pdf
57. McAfee PC, Geisler FH, Saiedy SS et al (2006) Revisability of
the CHARITE artiﬁcial disc replacement: analysis of 688 patients
enrolled in the U.S. IDE study of the CHARITE Artiﬁcial Disc.
Spine 31:1217–1226
58. FDA approval ProDisc: http://www.fda.gov/cdrh/pdf5/p050010a.
pdf
59. Geisler FH, Blumenthal SL, Guyer RD et al (2004) Neurological
complications of lumbar artiﬁcial disc replacement and compar-
ison of clinical results with those related to lumbar arthrodesis in
the literature: results of a multicenter, prospective, randomized
investigational device exemption study of Charite intervertebral
disc. J Neurosurg Spine 1:143–154
60. Leary SP, Regan JJ, Lanman TH et al (2007) Revision and
explantation strategies involving the CHARITE lumbar artiﬁcial
disc replacement. Spine 32:1001–1011
61. Punt IM, Visser VM, van Rhijn LW et al (2008) Complications
and reoperations of the SB Charite lumbar disc prosthesis:
experience in 75 patients. Eur Spine J 17:36–43
62. van Ooij A, Oner FC, Verbout AJ (2003) Complications of
artiﬁcial disc replacement: a report of 27 patients with the SB
Charite disc. J Spinal Disord Tech 16:369–383
63. van Ooji A, Schurink GW, Oner FC et al (2007) Findings in 67
patients with recurrent or persistent symptoms after implantation
Eur Spine J (2010) 19:1262–1280 1279
123of a disc prosthesis for low back pain. Ned Tijdschr Geneeskd
151:1577–1584
64. Kurtz SM, van Ooij A, Ross R et al (2007) Polyethylene wear and
rim fracture in total disc arthroplasty. Spine J 7:12–21
65. van Ooij A, Kurtz SM, Stessels F et al (2007) Polyethylene wear
debris and long-term clinical failure of the Charite disc prosthe-
sis: a study of 4 patients. Spine 32:223–229
66. Boden SD, Davis DO, Dina TS et al (1990) Abnormal magnetic-
resonance scans of the lumbar spine in asymptomatic subjects. A
prospective investigation. J Bone Joint Surg Am 72:403–408
67. Jensen MC, Brant-Zawadzki MN, Obuchowski N et al (1994)
Magnetic resonance imaging of the lumbar spine in people
without back pain. N Engl J Med 331:69–73
68. Button G, Gupta M, Barrett C et al (2005) Three- to six-year
follow-up of stand-alone BAK cages implanted by a single sur-
geon. Spine J 5:155–160
69. Lorenz M, Zindrick M, Schwaegler P et al (1991) A comparison
of single-level fusions with and without hardware. Spine
16:S455–S458
70. Pellise F, Puig O, Rivas A et al (2002) Low fusion rate after L5–
S1 laparoscopic anterior lumbar interbody fusion using twin
stand-alone carbon ﬁber cages. Spine 27:1665–1669
71. Brox JI, Reikeras O, Nygaard O et al (2006) Lumbar instru-
mented fusion compared with cognitive intervention and exer-
cises in patients with chronic back pain after previous surgery for
disc herniation: a prospective randomized controlled study. Pain
122:145–155
72. Van Tulder MW, Koes B, Seitsalo S et al (2006) Outcome of
invasive treatment modalities on back pain and sciatica: an evi-
dence-based review. Eur Spine J 15:S82–S92
73. Ostelo RWJG, Deyo RA, Stratford P et al (2008) Interpreting
change scores for pain and functional status in low back pain:
towards international consensus regarding minimal important
change. Spine 33:90–94
74. Hudson-Cook N, Tomes-Nicholson K, Breen A (1989) A revised
Oswestry disability questionnaire. In: Roland M, Jenner JR (eds)
Back pain: new approaches to rehabilitation and education.
Manchester University Press, Manchester, pp 187–204
75. Fairbank J (2007) Letter to the Editor. Spine 32(25):2929–2930
76. Stieber JR, Donald GD (2006) Early failure of lumbar disc
replacement: case report and review of the literature. J Spinal
Disord Tech 19:55–60
77. Zigler JE (2007) Letter to the editor. Spine 32(25):2930–2931
78. Brau SA (2002) Mini-open approach to the spine for anterior
lumbar interbody fusion: description of the procedure, results and
complications. Spine J 2:216–223
79. Bertagnoli R, Zigler J, Karg A et al (2005) Complications and
strategies for revision surgery in total disc replacement. Orthop
Clin North Am 36:389–395
80. Harrop JS, Youssef JA, Maltenfort M et al (2008) Lumbar
adjacent segment degeneration and disease after arthrodesis and
total disc arthroplasty. Spine 33:1701–1707
81. Putzier M, Funk JF, Schneider SV et al (2006) Charite total disc
replacement—clinical and radiographical results after an average
follow-up of 17 years. Eur Spine J 15:183–195
1280 Eur Spine J (2010) 19:1262–1280
123